Related Articles
Amicus Therapeutics Announces Positive Pompe Program Updates
Amicus Therapeutics Announces Positive Pompe Program Updates
March 19, 2012 Community Update for Pompe Families in the United States who Utilize Myozyme® (alglucosidase alfa) Produced at the 160 L Manufacturing Scale
POMP-US-P334-03-12 March 19, 2012 Community Update for Pompe Families in the United States who Utilize Myozyme® (alglucosidase alfa) Produced at the 160 L Manufacturing Scale We are writing to provide an update to those families who are currently receiving Myozyme...
ADVANCE Study Fact Sheet
ADVANCE Study Fact Sheet
Community Update for Pompe Families in the United States who Utilize Myozyme®
Community Update for Pompe Families in the United States who Utilize Myozyme®
AMICUS POMPE COMMUNITY UPDATE
AMICUS POMPE COMMUNITY UPDATE
Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
Sanofi-aventis to Acquire Genzyme
Sanofi-aventis to Acquire Genzyme
POMPE in COMMON
POMPE in COMMON
United States Pompe Program Update, August 9, 2010
United States Pompe Program Update, August 9, 2010
United States Pompe Program Update, May 25, 2010
United States Pompe Program Update, May 25, 2010